Towards new antifolates targeting eukaryotic opportunistic infections

Eukaryotic Cell

Volumn 8, Issue 4, 2009, Pages 483-486

  Liu, Jieying ^a   Bolstad, David B ^a   Bolstad, Erin S D ^a   Wright, Dennis L ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; FUNGAL PROTEIN; PROTOZOAL PROTEIN; TRIMETHOPRIM;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CANDIDA GLABRATA; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULAR GENETICS; OPPORTUNISTIC INFECTION; PARASITOLOGY; PNEUMOCYSTIS; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; TOXOPLASMA;

AMINO ACID SEQUENCE; ANIMALS; CANDIDA GLABRATA; DRUG DESIGN; FOLIC ACID ANTAGONISTS; FUNGAL PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS; PROTOZOAN PROTEINS; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TRIMETHOPRIM;

CANDIDA GLABRATA; CRYPTOSPORIDIUM; EUKARYOTA; FUNGI; PNEUMOCYSTIS; PROKARYOTA; PROTOZOA; TOXOPLASMA;

EID: 64749114314     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.00298-08     Document Type: Article

References (32)

1. Abubakar, I., S. Aliyu, C. Arumugam, N. Usman, and P. Hunter. 2007. Treatment of cryptosporidiosis in immunocompromised individuals: systemic review and meta-analysis. Br. J. Clin. Pharmacol. 63:387-393.
2. Allegra, C, B. Chabner, C. Tuazon, D. Ogata-Arakaki, B. Baird, J. Drake, J. Simmons, E. Lack, J. Shelhamer, F. Balis, R. Walker, J. Kovacs, H. Lane, and H. Masur. 1987. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 317:978-985.
3. Anderson, A. 2005. Targeting DHFR in parasitic protozoa. Drug Discov. Today 10:121-128.
4. Anderson, A. 2005. Two crystal structures of dihydrofolate reductase-thymidylate synthase from Cryptosporidium hominis reveal protein:ligand interactions including a structural basis for observed antifolate resistance. Acta Crystallogr. F 61:258-262.
5. Bertino, J. 1993. Karnofsky Memorial Lecture: ode to methotrexate. J. Clin. Oncol. 11:5-14.
6. Chan, D., and A. Anderson. 2006. Towards species-specific antifolates. Curr. Med. Chem. 13:377-398.
7. Cody, V. 2002. Structure-based modeling of reversed N9-C10 bridge antifols with human, Pc and Tg DHFR, p. 525-529. In Chemistry and biology of pteridines and folates. Proceedings of the 12th International Symposium on Pteridines and Folates. National Institutes of Health, Bethesda, MD.
8. Cody, V., N. Galitsky, D. Rak, J. Luft, W. Pangborn, and S. Queener. 1999. Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and Nadp + . Biochemistry 38:4303-4312.
9. Cody, V., J. Pace, K. Chisum, and A. Rosowsky. 2006. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent trimethoprim derivatives. Proteins 65:959-969.
10. Gangjee, A., O. Adair, and S. Queener. 2003. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d] pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J. Med. Chem. 46:5074-5082.
11. Gangjee, A., and X. Lin. 2005. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase and rat liver dihydrofolate reductase. J. Med. Chem. 48:1448-1469.
12. Gangjee, A., X. Lin, and S. E. Queener. 2003. 7-Methyl trimethoprim analogs as inhibitors of the folate metabolizing enzymes. J. Heterocyclic Chem. 40:507-512.
13. Hajjeh, R., A. Sofair, L. Harrison, G. M. Lyon, B. Arthington-Skaggs, S. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. Ciblak, L. Benjamin, L. Sanza, S. Huie, S. Yeo, M. Brandt, and D. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
14. Hawser, S., S. Luciuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71:941-948.
15. Kamchonwongpaisan, S., R. Quarrell, N. Chareonsethakul, R. Ponsinet, T. Vilaivan, J. Vanichtanankul, B. Tarnchompoo, W. Sirawaraporn, G. Lowe, and Y. Yuthavong. 2004. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J. Med. Chem. 47:673-680.
16. Liu, J., D. Bolstad, A. Smith, N. Priestley, D. Wright, and A. Anderson. 2008. Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase. Chem. Biol. 15:990-996.
17. Ma, L., L. Borio, H. Masur, and J. Kovacs. 1999. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180:1969-1978.
18. Ma, L., and J. Kovacs. 2000. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob. Agents Chemother. 44:3092-3096.
19. Murshudov, G., A. Vagin, and E. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53:240-255.
20. Nahimana, A., M. Rabodonirina, J. Bille, P. Francioli, and P. Hauser. 2004. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob. Agents Chemother. 48:4301-4305.
21. Pelphrey, P., V. Popov, T. Joska, J. Beierlein, E. Bolstad, Y. Fillingham, D. Wright, and A. Anderson. 2007. Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J. Med. Chem. 50:940-950.
22. Pfaller, M., and D. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
23. Queener, S., M. Bartlett, M. Jay, M. Durkin, and J. Smith. 1987. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob. Agents Chemother. 31:1323-1327.
24. Rosowsky, A., H. Chen, H. Fu, and S. Queener. 2003. Synthesis of new 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrrolo[2,3-d]pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii and Mycobacterium avium dihydrofolate reductase. Bioorg. Med. Chem. 11:59-67.
25. Rosowsky, A., R. Forsch, and S. Queener. 2002. Inhibition of Pneumocystis carinii, Toxoplasma gondii and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(ω-carboxyalkoxy) benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J. Med. Chem. 45:233-241.
26. Rosowsky, A., R. Forsch, and S. Queener. 2003. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem. 46:1726-1736.
27. Rosowsky, A., R. Forsch, C. Sibley, C. Inderlied, and S. Queener. 2004. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. J. Med. Chem. 47:1475-1486.
28. Takahashi, T., T. Endo, T. Nakamura, H. Sakashitat, K. Kimurat, K Ohnishit, Y. Kitamura, and A. Iwamoto. 2002. Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan. J. Med. Microbiol. 51:510-515.
29. Trick, W., S. Fridkin, J. Edwards, R. Hajjeh, and R. Gaynes. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-630.
30. Tzipori, S., and G. Widmer. 2008. A hundred-year retrospective on cryptosporidiosis. Trends Parasitol. 24:184-189.
31. Walzer, P., J. Foy, P. Steele, C. K. Kim, M. White, R. Klein, B. Otter, and C. Allegra. 1992. Activities of antifolate, antiviral and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36:1935-1942.
32. Whitlow, M., A. Howard, D. Stewart, K. Hardman, L. Kuyper, D. Baccanari, M. Fling, and R. Tansik. 1997. X-ray crystallographic studies of Candida albicans dihydrofolate reductase. J. Biol. Chem. 272:30289-30298.